Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie
Biosimilars Body Points To Letters And Materials From Humira Originator
AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.
You may also be interested in...
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.
Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.